Presentations 2015

15th European AIDS Conference (EACS) 21-24 October 2015

Oral presentations 
One-year Mortality of HIV-patients Treated for Susceptible TB is Higher in Eastern Europa Than in Western/Southern Europe and Latin America, presented by Daria Podlekareva on behalf of the TB:HIV study group in EuroCoord. PS2/2.  PRESENTATION


Where is the greatest impact of uncontrolled HIV Iinfection on clinical disease progression? presented by Amanda Mocroft on behalf of EuroSIDA in EuroCoord. PS8/6. PRESENTATION

Testing patterns and predictive value of Prostate Specific Antigen in a European HIV-positive cohort: Does size fit all? presented by Leah Shepherd on behalf of EuroSIDA in EuroCoord. PS5/5. PRESENTATION

Trends in incidences and risk factors for hepatocellular carcinoma & other liver events in HIV/HCV co-infected individuals from 2001 to 2014: a multi-cohort study, presented by Lars Iversen Gjærde (collaboration). PS7/2. PRESENTATION 

Is Response to Anti-HCV Treatment Predictive of Mortality in HCV/HIV Co-infected Patients? presented by Lars Peters on behalf of COHERE in EuroCoord. PRESENTATIONMEDIA

HIV/HCV-coinfection across Europe, presented by Lars Peters on behalf of EuroSIDA in EuroCoord. PE13/23. POSTER

Uptake of tenofovir-based combination antiretroviral therapy among HIV/HBV Co-infected patients in the EuroSIDA Study, presented by Lars Peters on behalf of EuroSIDA in EuroCoordPE13/4. POSTER

Comparison of the Risk of Resistance Accumulation According to ART Switching Strategies after Virological Failure >200 Copies/mL to First cART Using the g-computation Procedure, presented by Alessandro Cozzi-Lepri on behalf of EuroSIDA in EuroCoord. PE9/11. POSTER

Inter- and intra-regional variability in the degree of ART-induced HIV-RNA suppressionpresented by Kamilla Grønborg Laut on behalf of EuroSIDA in EuroCoord. PE8/71. POSTER

Long-term Virological Outcomes of ART-experienced Patients Receiving Raltegravir in a Large European Cohort Study, presented by Anna Schultze on behalf of EuroSIDA in EuroCoord. POSTER

Incidence of cancer in individuals treated with raltegravir-based and non-raltegravir-based cART regimens, presented by Alessandro Cozzi-Lepri on behalf of EuroSIDA in EuroCoord. POSTER

Ongoing Mononucleosis-like Illness – A Clear Indicator Condition for HIV Testing:  Results from the HIDES 2 Study – Single Arm Extension, D. Raben et al., on behalf of the HIDES Mono Extension Study Group. POSTER 

HCV-RNA profiles among HIV/HCV coinfected individuals in the ESPRIT study; spontaneous HCV-RNA clearance documented in 9 individuals, presented by Daniel Grint. POSTER

Impact of Decentralized Drug Purchase on Antiretroviral Treatment Costs in SpainY. Rivero-Montesdeoca et al., CEVIH Group for OptTEST by HIV in Europe. POSTER 

Evaluation of HIV Testing Recommendations In Specialty Guidelines for the Management of HIV Indicator Conditions, E Lord et al., BHIVA/BASHH Guideline Review Group for OptTEST by HIV in Europe. POSTER 

Linkage to Care Following HIV Diagnosis in Europe: A Review of the Literature, S Croxford et al., for OptTEST by HIV in Europe. POSTER 

Healthcare Related Costs of Missed Opportunities for HIV Diagnosis: A Potential Driver to Increase Indicator Condition Guided HIV Testing, C. Rae et al., for OptTEST by HIV in Euope. POSTER 

Direct Costs of HIV/AIDS Care in Estonia, L. Lemsalu et al., for OptTEST by HIV in Europe. POSTER

Is Nelfinavir Exposure Associated with Cancer Incidence in HIV-positive individuals?  DC Boettiger et. al presented by Caroline Sabin. POSTER

ID Week 2015 7-11 October 2015
EBV DNAemia and Post-transplant Lymphoproliferative Disorders (PTLD) among Transplant Recipients. Presented by Neval Ete Wareham et al. on behalf of MATCH in PERSIMUNE study group. POSTER

Non-recognized liver impairment in critically ill patients is frequent and hazardous. Presented by JU Jensen et al. on behalf of the Procalcitonin An Survival (PASS) Group and the Cooling and Surviving Septic Shock (CASS) Group. POSTER

Cytomegalovirus (CMV) Viral Load in Bronchoalveolar Lavage Fluid (BALF) and Plasma to Diagnose Lung Transplant Associated CMV Pneumonia. Presented by Paula Isabelle Lodding et al. on behalf of MATCH in PERSIMUNE study group. Presentation

8th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 2015


Oral presentation


1 Excess TB mortality in HIV patients in Eastern Europe: restructured approach to care needed. Presented by Anna Schultze on behalf of the TB:HIV study group in EuroCoord. Monday 20th July 11:30-11:45 Ballroom C-D. Session Title: HIV and TB: Gaps and Opportunities. Abstract number MOAB0203.

22nd Conference on Retroviruses and Opportunistic Infections (CROI), 23-26 February 2015, Seattle, Washington


A Prognostic Score Estimating the Risk of Liver-Related Death Among HIV/HCV Coinfected Subjects, presented by Amanda Mocroft, submitting author: Daniel Grint. Session P-N1, February 24th 2.30-4.00 PM. Abstract number 637. POSTER

New Marker of Standard-of-ART Care: Percentage of Time on cART With Suppressed HIV-RNA, presented by Kamilla Laut. Session P-K2, February 24th 2.30-4.00PM. Abstract number 561. POSTER

Relationship Between Confirmed eGFR and Cardiovascular Disease in HIV-Positive Persons, presented by Lene Ryom. Session P-P4, February 24th 2.30-4.00PM. Abstract number 742. POSTER

Antiretroviral Drugs Associated With Chronic ALT Elevations in Persons Without HCV and HBV Infection, presented by Helen Kovari. Session P-Q12, February 26th 2.30-4.00PM. Abstract number 805. POSTER

Impact of Antiretroviral Drugs on Hypertension in HIV-Positive Persons: D:A:D Study, presented by Camilla Hatleberg. Session P-P3, February 25th 2.30-4.00PM. Abstract number 739. POSTER

Impact of Specific Antiretroviral Drugs on Non-AIDS Mortality; the D:A:D Study, presented by Camilla Hatleberg. Session P-K4, February 25th, 2.30-4.00PM. Abstract number 582. POSTER

IL-6 is a stronger predictor of clinical events then hsCRP or D-dimer in HIV disease, presented by Alvaro Borges, Session P-Q1, 24th February 2:30-4:30PM. Abstract number 761. POSTER

Oral Presentation:

Exposure to Antiretrovirals (ARVs) and Development of Chronic Kidney Disease (CKD), presented by Prof Amanda Mocroft. Session O-11 Cardiovascular, Bone, and Kidney Health, 10.00AM-12.15PM Room 6C. Abstract number 142PRESENTATION

The International Liver Congress 2015, Vienna Austria 22-26 April 2015

A systematic review of hepatitis B and C testing in the countries of the WHO European Region presented by Jeffrey Lazarus PRESENTATION. Abstract

Strengthening viral hepatitis surveillance in Europe: recommendations from two global hepatitis policy surveys (2013 and 2014) presented by Jeffrey Lazarus. POSTER. Abstract

XXIV International Drug Resistance Workshop, 21-22 February, Seattle, Washington


Rate of Accumulation of Drug Resistance Mutations during Virological Failure According to Different Measures of Viral Load Exposure, Presented by Anna Schultze, on behalf of EuroSIDA in EuroCoord. Poster number 29. POSTER